chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient recieved 1st dose of Moderna vaccine on 4/10/21. He reported that he has itchiness/hives last 10-20min. he said that it moves around on different parts of his body, feet, then back to legs. Yesterday he said that it was on his wrist. It subsided and then flares up again.  Patient said that it started about 2 to 3 days after the vaccination.
Muscle pain, from lower back down.; I had no feeling at all below the waist; fatigue; Muscles would feel like they were seizing up and clenching throughout the night; This is a spontaneous report from a contactable nurse. A 39-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number EK9231) , via an unspecified route of administration in left arm on 07Jan2021 18:30 at a single dose for COVID-19 immunization. The vaccine was administered in a hospital. Medical history included Von Willebrand's disease. The patient had no known allergies. The patient was not diagnosed with COVID-19 prior to vaccination. Concomitant medication included ibuprofen. On 07Jan2021 23:00, the patient experienced muscle pain, from lower back down, Muscles would feel like they were seizing up and clenching throughout the night, for a short time she had no feeling at all below the waist and incredible fatigue. The outcome of the events was not recovered. The patient was not tested for COVID-19 post vaccination. The events was assessed as non-serious by the nurse. The patient did not received any treatment for the events.
Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On or about 13-OCT-2012, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided), at a pharmacy, as recommended for routine adult health maintenance and for the long-term prevention of shingles and zoster related injuries. The vaccine did not prevent shingles and zoster-related injuries as intended. In or around OCTOBER 2016, the patient was treated by a healthcare facility/hospital, for the onset of a rash, which was diagnosed as Herpes zoster or shingles. As a direct and proximate result of the ZOSTAVAX vaccine, and or despite receiving ZOSTAVAX vaccine for the long-term prevention of shingles and zoster-related injuries, the patient suffered and continues to suffer painful and ongoing injuries and damages and required and continues to require extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown.  Causality assessment was related. Additional information has been requested.
Intense,  sudden onset of gastrointestinal distress, diarhhea, vomiting lasting for approximately 30 minutes.  Followed by 3 days on on-going discomfort, heartburn and lower GI symptoms.  Eating small amounts of a bland diet.  My husband had his vaccine 2 days after mine and and 48 hours later is experiencing the same symptoms.
Three weeks after 5th vaccine started feeling extreme chills and headache. Three days later took a home COVID-19 test and was positive. Went to Primary Care Doctor and prescribed Paxlovid.
Patient developed rash (urticaria) the evening after receiving the flu vacc. and itching.
10/1/2021 5:30 AM very intense nose bleed out of left nostril, lasted for about 30 minutes. Nose bleed started back 10/1/2021 10:00 AM, not as intense, lasted about 20 minutes. Never had a nose bleed before in my life and does not run in the family.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). An 11-year-old male patient received BNT162b2 (BNT162B2), on 28Nov2021 at 13:00 as dose 1, single (Lot number: FK5127) at the age of 10 years intramuscular, in left arm for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: LYMPHADENOPATHY (non-serious) with onset 22May2022, outcome "unknown", described as "Armpit swollen"; AXILLARY PAIN (non-serious) with onset 22May2022, outcome "unknown", described as "Armpit swollen and pain"; AXILLARY MASS (non-serious) with onset 22May2022, outcome "unknown", described as "lump under armpit". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of lymphadenopathy, axillary pain, axillary mass. Additional information: It was reported that no specific relevant test for thromboembolic events with thrombocytopenia. Event required the initiation of new medication/other treatment/ procedure and the same were occurred at 1 and 2nd dose, but less severe. No follow-up attempts are needed. No further information is expected.
Feverish; Bone aches; Tired; Small movable lump under my armpit; This spontaneous case was reported by a nurse and describes the occurrence of AXILLARY MASS (Small movable lump under my armpit), PYREXIA (Feverish), BONE PAIN (Bone aches) and FATIGUE (Tired) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 001B21A and 031M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 13-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Mar-2021, the patient experienced AXILLARY MASS (Small movable lump under my armpit). On 15-Mar-2021, the patient experienced PYREXIA (Feverish), BONE PAIN (Bone aches) and FATIGUE (Tired). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form. At the time of the report, AXILLARY MASS (Small movable lump under my armpit), PYREXIA (Feverish), BONE PAIN (Bone aches) and FATIGUE (Tired) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant medications were reported.
Narrative: Pt reported frontal headache after 1st Pfizer COVDI-19 vaccine. PMH significant for insulin-dependent diabetes. Last insulin administration was last night, ate meals today, last fingerstick glucose reading was 3 days prior. Patient reported feeling dry and headache receded after water bottle was drank. Patient received 2nd dose of Pfizer 3 weeks later with no complaints.
Initial unsolicited report received from a pharmacist on 12-Oct-2016. This case was linked with cases 2016SA189772, 2016SA189781, 2016SA189791, 2016SA189792, 2016SA189793, 2016SA189794, 2016SA189795, 2016SA189796, 2016SA189797, 2016SA189798, 2016SA189799, 2016SA189800, 2016SA189801, 2016SA189802, 2016SA189804, 2016SA189805, 2016SA189806, 2016SA189807, 2016SA189808, 2016SA189809, 2016SA189810, 2016SA189811, 2016SA189812, 2016SA189813, 2016SA189814, 2016SA189815, 2016SA189816, 2016SA189817, 2016SA189818, 2016SA189819, 2016SA189820, 2016SA189821, 2016SA189822, 2016SA189823, 2016SA189824, 2016SA189825, 2016SA189826, 2016SA189827, 2016SA189828, 2016SA189829, 2016SA189830, 2016SA189831, 2016SA189832, 2016SA189833, 2016SA189834, 2016SA189835, 2016SA189836, 2016SA189837, 2016SA189838, 2016SA189839, 2016SA189840, 2016SA189841, 2016SA189842, 2016SA189843, 2016SA189844, 2016SA189845, 2016SA189846, 2016SA189847, 2016SA189848. (Same vaccine). This case involves a patient (gender and age not reported) who was vaccinated with a dose of FLUZONE via intramuscular route (Batch number: UI669AA, expiry date: 30-Jun-2017, dose, dose in series and site of administration were not reported) on 04-Oct-2016. Patient's pre-existing physician diagnosed allergies, birth defects, medical conditions was unknown. Illness at the time of vaccination was also reported as unknown. No further information regarding medical history was available. Concomitant medications were not reported. Any other vaccinations within four weeks of vaccinations were also not reported. On 05-Oct-2016, one day following the vaccination (reported as throughout the night of 05-Oct-2016), the patient developed pain in axillary area, burning and headache. Patient required emergency room (ER)/ doctor visit. Laboratory investigations was not reported. Corrective treatment was reported as 'no'. The outcome of events burning and headache was reported as unknown and the event pain was not recovered at the time of reporting (reported as 'still pain in underarm area'). List of documents held by sender: none.
Feeling really rough; This case was reported by a consumer via interactive digital media and described the occurrence of feeling unwell in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 21st September 2021, the patient received the 1st dose of Shingles vaccine. In September 2021, less than a week after receiving Shingles vaccine, the patient experienced feeling unwell. On an unknown date, the outcome of the feeling unwell was not recovered/not resolved.   It was unknown if the reporter considered the feeling unwell to be related to Shingles vaccine.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not reported. The patient got the first vaccine and had been feeling really rough and all.
Information has been received from a physician concerning 200 unspecified patients. The patients' medical history, concurrent conditions and concomitant therapies were not reported. On unknown dates between 2014 and 2015, improperly stored doses of VARIVAX (dose, route, lot# and expiry date were unknown) were administered to the patients for prophylaxis. The doses of measles, mumps, rubella and VARIVAX were exposed to a temperature excursion of -14 to -10 Celsius degree (time frame unknown), which was detected by data logger. There was multiple temperature excursions (unspecified details). No adverse events were reported. All telephone attempts to obtain follow up information had been unsuccessful. This is one of two reports from the same reporter.; Sender's Comments:  US-009507513-1706USA007775:
Bad migraine since 2nd shot; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 32030bd) via an unspecified route of administration in the left arm on 09Nov2021 at 16:30 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not take any concomitant medications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FF8841) via an unspecified route of administration in the left arm on 19Oct2021 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. On 09Nov2021 at 16:30, the patient experienced bad migraine since the 2nd shot. The event did not result in doctor or other healthcare professional office or clinic visit and emergency room or department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event bad migraine since the 2nd shot was not recovered at the time of this report.
12 hours after vaccination- fever, fatigue, chills treated with ibuprofen  24 hours after vaccination- fever continued to treat with ibuprofen. Stomach pains/diarrhea
Arm became swelled on inside blocking blood flow. (edema). Nausea and vomiting and pain. Went to ER gave IV fluids.
show symptoms of COVID-19/positive for COVID-19; This is a spontaneous report from a contactable consumer or other non hcp. A 44-years-old male patient received BNT162B2(BNT162B2), dose 1 via an unspecified route of administration, administered in arm right on 20Apr2021 13:30 (Batch/Lot Number: EP7533; Expiration Date: 31Jul2021) as 1st dose, single for covid-19 immunisation. The patient medical history was reported as none. The patient concomitant medications were not reported. The patient family medical history relevant to event was none. History of all previous immunization with the Pfizer vaccine considered as suspect was none. Additional Vaccines Administered on Same Date of the Pfizer Suspect was none. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021, patient developed symptoms of Covid and on 23Apr2021, he tested positive for the Covid infection. The caller states that she was wondering if he should get the second vaccine. The events not resulted in emergency room/physician office. The patient underwent lab tests and procedures which included sars-cov-2 test negative: negative on 07May2021, sars-cov-2 test positive: positive on 23Apr2021. Therapeutic measures included: None, he stayed home, and after 14 days, he got a negative result test for Covid on 07May2021. Reporter seriousness for Tested positive for Covid 19 on 23Apr2021, after receiving the first dose of the Covid vaccine on 20Apr2021, with symptoms starting on 22Apr2021: Unspecified. The outcome of the event was recovered on 07May2021.   No follow-up attempts are needed. No further information is expected.
sick; he had a bad headache; running a fever, 101.5 for a couple of days; very extremely tired from Sunday until today; This is a spontaneous report from a contactable consumer (patient's father in law). A 30-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date in Mar2021 as dose 2, single for COVID-19 immunisation. The patient's  medical history and concomitant medications were not reported. On an unspecified date in Mar2021 (Sunday), patient received the second dose and he was sick for 4 days and had a bad headache, running fever, where temperature of 101.5 for a couple of days, and he was extremely tired from Sunday until at the time of report. The outcome of the event extremely tired was not recovered and of other events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient received a Booster dose with more than 0.25ML.; This spontaneous case was reported by an other health care professional and describes the occurrence of ACCIDENTAL OVERDOSE (Patient received a Booster dose with more than 0.25ML.) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ACCIDENTAL OVERDOSE (Patient received a Booster dose with more than 0.25ML.). At the time of the report, ACCIDENTAL OVERDOSE (Patient received a Booster dose with more than 0.25ML.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant drugs were not reported. Treatment medications were not provided.   Reporter did not allow further contact
No adverse effect reported.; child moved while receiving M-M-R II dose today and did not receive a full dose; Information has been received from a nurse, referring to a child of unknown age and gender. Information about medical history, concurrent condition and concomitant therapy was unknown.   On 21-OCT-2019, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) (one dose; strength, route, lot# and expiration date were unknown)  for prophylaxis. The child moved while receiving measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) dose and did not receive a full dose. No adverse effect was reported.
fatigue; fever; This case was reported by a consumer via call center representative and described the occurrence of fatigue in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   In November 2018, the patient received the 1st dose of Shingrix. In November 2018, several hours after receiving Shingrix, the patient experienced fatigue and fever. On an unknown date, the outcome of the fatigue and fever were recovered/resolved.   It was unknown if the reporter considered the fatigue and fever to be related to Shingrix.  Additional details were provided as follows:  The age at vaccination was not reported. The patient received the 1st dose in November 2018 in the mid afternoon in left arm. On next morning about 2 hours after getting up she experienced fatigue that put her back in bed.  The patient also had a 101 degree fever.  The symptoms resolved by the next day. The reporter did not consent to follow up. This case has been linked with case US2019120314, reported by the same reporter.
This case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a 18-year-old female patient who received BEXSERO. On 17th August 2017, the patient received the 2nd dose of BEXSERO. On 17th August 2017, less than a day after receiving BEXSERO, the patient experienced injection site erythema. On 18th August 2017, the patient experienced nausea. On an unknown date, the outcome of the injection site erythema and nausea were unknown. It was unknown if the reporter considered the injection site erythema and nausea to be related to BEXSERO. Additional details were provided as follows: The patient reported redness at the injection site and nausea, which began one day after vaccination with BEXSERO. The report was received from the patient's mother. It was reported that, she was not happy that she could not tell her how long nausea lasts and was referred to her healthcare professional.
Urticaria/hives per Dr visit on 1/26/21 Itching/rash  Allergy meds and femotidine (pepcid) I'm Still on medication  Treatment started on 1/26/21
pt recvd vax & 2-3 days p/dose pt stopped eating, was tired, white fecal matter & was nauseous for 2 wks; sx of stopped eating & tiredness subsided; exp vomiting for apporx 1 day lead to dehydration; taken to ER hospitalized;
7:15pm patient was given flu shot, within 2 minutes, pt had passed out, but came to w/in a minute. Stated felt dizzy, woozy, clammy. (Had a drink prior to shot).
Couldn't move from one side of the bed to the next couldn't move; Sick; Chills; This spontaneous case was reported by a consumer and describes the occurrence of MOVEMENT DISORDER (Couldn't move from one side of the bed to the next couldn't move), ILLNESS (Sick) and CHILLS (Chills) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 immunisation.     No Medical History information was reported.    On 04-Mar-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced MOVEMENT DISORDER (Couldn't move from one side of the bed to the next couldn't move), ILLNESS (Sick) and CHILLS (Chills). At the time of the report, MOVEMENT DISORDER (Couldn't move from one side of the bed to the next couldn't move), ILLNESS (Sick) and CHILLS (Chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       no concomitant medications are provided. treatment to the events not reported.
Information has been received from a nurse practitioner concerning a 15 year old female who on 03-AUG-2007 was vaccinated with Gardasil vaccine (lot # unknown). On 30-AUG-2007, the patient experienced "photosensitivity like reactions." The patient had a sunburn on her face, eye lids and neck and eventually the skin started peeling off those areas. The patient was not exposed to the sun more than usual and was using sunscreen. The patient also experienced rash on her legs. On 05-NOV-2007, the patient was vaccinated with a second dose of Gardasil vaccine (lot # unknown). The patient experienced similar symptoms but not as severe as after the first dose. No further information was provided. At the time of reporting it was unknown if the patient had recovered. Additional information has been requested. Initial and follow-up information has been received from an urse practitioner concerning a 15 year old female who in 30-AUG-2007 was vaccinated with a first dose og HPV vaccine (lot # unknown). On 30-AUG-2007 the patient experienced "photosensitivity like reactions". The patient had a sunburn on her face, eye lids and neck and eventuallly the skin started peeling off those areas. The patient was not exposed to the sun more than usual and was using sunscreen. The patient also experienced rash on her legs. Subsequently, the patient recovered. On 05-NOV-2007 the patient was vaccinated intramuscularly into the left deltoid with a second dose of HPV vaccine (lot # 658563/1063U). The patient experienced similar symptom of eyelids, face and neck peeled, rash on legs, and she felt "on fire". The symptoms were not as severe as after the first dose. The patient did not have a fever or pain. In November 2007, the patient recovered. Additional information is not expected.
Swelling, pain, redness, left neck to ear. Temperature 99.0 F. Pain increased with eating. symptoms wax and wane. Primary physician not in office but nurse advised me to see Dentist.
Marked arm swelling and erythema from shoulder to mid-forearm with arm pain. Treated with prednisone and cold compresses.
sore throat; temperature as high as 101.5; chills; headache; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (sore throat), BODY TEMPERATURE INCREASED (temperature as high as 101.5), CHILLS (chills) and HEADACHE (headache) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event .     On 25-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced OROPHARYNGEAL PAIN (sore throat), BODY TEMPERATURE INCREASED (temperature as high as 101.5), CHILLS (chills) and HEADACHE (headache). At the time of the report, OROPHARYNGEAL PAIN (sore throat), BODY TEMPERATURE INCREASED (temperature as high as 101.5), CHILLS (chills) and HEADACHE (headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided No treatment information provided
37 wks following vax, pt went into premature labor; Did not progress past 6cm dilation;and underwent a cesarean section; Infant weighed 5lbs 6oz had an apgar of 9 at one min & 10 at 5min;